SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-267677"
 

Sökning: id:"swepub:oai:DiVA.org:uu-267677" > Continuous inhibiti...

Continuous inhibition of 11 beta-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice

Gutierrez, P. Morentin (författare)
AstraZeneca R&D, Mereside, Macclesfield SK10 4TG, Cheshire, England.
Gyte, A. (författare)
AstraZeneca R&D, Mereside, Macclesfield SK10 4TG, Cheshire, England.
deSchoolmeester, J. (författare)
AstraZeneca R&D, Mereside, Macclesfield SK10 4TG, Cheshire, England.
visa fler...
Ceuppens, P. (författare)
AstraZeneca R&D, Mereside, Macclesfield SK10 4TG, Cheshire, England.
Swales, J. (författare)
AstraZeneca R&D, Mereside, Macclesfield SK10 4TG, Cheshire, England.
Stacey, C. (författare)
AstraZeneca R&D, Mereside, Macclesfield SK10 4TG, Cheshire, England.
Eriksson, Jan W. (författare)
Uppsala universitet,Klinisk diabetologi och metabolism,AstraZeneca R&D, Molndal, Sweden.
Sjostrand, M. (författare)
AstraZeneca R&D, Molndal, Sweden.
Nilsson, C. (författare)
AstraZeneca R&D, Molndal, Sweden.
Leighton, B. (författare)
AstraZeneca R&D, Mereside, Macclesfield SK10 4TG, Cheshire, England.
visa färre...
AstraZeneca R&D, Mereside, Macclesfield SK10 4TG, Cheshire, England Klinisk diabetologi och metabolism (creator_code:org_t)
2015-10-08
2015
Engelska.
Ingår i: British Journal of Pharmacology. - : Wiley. - 0007-1188 .- 1476-5381. ; 172:20, s. 4806-4816
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background and Purpose11-hydroxysteroid dehydrogenase type I (11-HSD1), a target for Type 2 diabetes mellitus, converts inactive glucocorticoids into bioactive forms, increasing tissue concentrations. We have compared the pharmacokinetic-pharmacodynamic (PK/PD) relationship of target inhibition after acute and repeat administration of inhibitors of 11-HSD1 activity in human, rat and mouse adipose tissue (AT). Experimental ApproachStudies included abdominally obese human volunteers, rats and mice. Two specific 11-HSD1 inhibitors (AZD8329 and COMPOUND-20) were administered as single oral doses or repeat daily doses for 7-9days. 11-HSD1 activity in AT was measured ex vivo by conversion of H-3-cortisone to H-3-cortisol. Key ResultsIn human and rat AT, inhibition of 11-HSD1 activity was lost after repeat dosing of AZD8329, compared with acute administration. Similarly, in rat AT, there was loss of inhibition of 11-HSD1 activity after repeat dosing with COMPOUND-20 with continuous drug cover, but effects were substantially reduced if a drug holiday' period was maintained daily. Inhibition of 11-HSD1 activity was not lost in mouse AT after continuous cover with COMPOUND-20 for 7days. Conclusions and ImplicationsHuman and rat AT, but not mouse AT, exhibited tachyphylaxis for inhibition of 11-HSD1 activity after repeat dosing. Translation of observed efficacy in murine disease models to human for 11-HSD1 inhibitors may be misleading. Investigators of the effects of 11-HSD1 inhibitors should confirm that desired levels of enzyme inhibition in AT can be maintained over time after repeat dosing and not rely on results following a single dose.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy